Exelixis ( (EXEL) ) has released its Q3 earnings. Here is a breakdown of the information Exelixis presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Exelixis, Inc. is a biotechnology company focused on developing and commercializing cancer therapies, with a strong emphasis on its cabozantinib franchise and expanding pipeline of oncology treatments.
In the third quarter of 2025, Exelixis reported significant financial growth, with total revenues reaching $597.8 million, driven largely by the success of its cabozantinib franchise. The company also highlighted progress in its clinical trials and pipeline development, particularly with the positive results of the STELLAR-303 trial for zanzalintinib.
Key financial metrics for Exelixis included a GAAP diluted EPS of $0.69 and a non-GAAP diluted EPS of $0.78. The company announced a new stock repurchase program of up to $750 million by the end of 2026. Additionally, Exelixis reported a decrease in research and development expenses and an increase in selling, general, and administrative expenses compared to the previous year.
Exelixis is optimistic about its future, with plans to submit a new drug application for zanzalintinib in the U.S. by the end of 2025. The company continues to focus on expanding its clinical trials and advancing its early-stage pipeline, aiming to improve cancer treatment standards and patient outcomes.